Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 2/20 | 0.65 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.65 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.65 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.65 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.59 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | BRAF | P15056 | 4/20 | 0.58 |
| ▸ | RAF1 | P04049 | 2/20 | 0.58 |
| ▸ | CSF1R | P07333 | 3/20 | 0.58 |
| ▸ | BTK | Q06187 | 3/20 | 0.58 |
| ▸ | KIT | P10721 | 2/20 | 0.58 |
| ▸ | LCK | P06239 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24275085 | 0.86 | KCNQ3 (0.65) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL16036513 | 0.86 | KCNQ3 (0.65) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL21877180 | 0.85 | KCNQ3 (0.63) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL26075509 | 0.85 | KCNQ3 (0.63) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL25344781 | 0.82 | KCNQ3 (0.60) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL4436924 | 0.82 | RAF1 (0.69) | PTGS1BRAFRAF1BTK | |
| SCHEMBL2883773 | 0.81 | MEN1 (0.68) | MEN1HTTRAB9AKMT2AKCNK3 | |
| SCHEMBL3942796 | 0.81 | GAA (0.63) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL4445721 | 0.80 | RAF1 (0.59) | BRAFRAF1 | |
| SCHEMBL23482407 | 0.79 | RAF1 (0.67) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841318-B2 | Substituted heterocycles as janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2013-10-17 | — | — | US | disclosed |
| US-8513270-B2 | Substituted heterocycles as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2121692-B1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORP (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2121692-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080188500-A1 | e.g. N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide; Janus kinases inhibitor; anticarcinogenic agent; immune-related diseases, skin disorders, myeloid proliferative disorders | INCYTE CORPORATION | 2008-08-07 | — | — | US | disclosed |
| WO-2008079965-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188500-A1 | e.g. N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide; Janus kinases inhibitor; anticarcinogenic agent; immune-related diseases, skin disorders, myeloid proliferative disorders | JAK3, JAK1, JAK2 | KCNQ3 2899/4885KCNQ2 2892/4885KCNE1 2172/4885 |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | KCNQ3 3242/4885KCNQ2 3208/4885KCNE1 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.